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MaBACKGROUND Myocardial injury after transcatheter aortic valve replacement (TAVR) is common, but its cause and
relationship to the extent of myocardial tissue loss remain unclear.
OBJECTIVES This study sought to examine the incidence and degree of ischemic myocardial damage using cardiac
magnetic resonance imaging and myocardial biomarkers in patients undergoing TAVR.
METHODS Patients with severe aortic stenosis (n ¼ 61) underwent cardiac magnetic resonance imaging before and after
TAVR for the assessment of new myocardial injury. High-sensitivity cardiac troponin T and creatine kinase-myocardial
band were measured before and at 24, 48, and 72 h after TAVR.
RESULTS After TAVR, new myocardial late enhancement (LE) with an ischemic pattern occurred in 11 patients (18%),
with a mean mass of 3.7 g (interquartile range: 1.2 to 6 g) or 1.8% (interquartile range: 1.3% to 4.1%) of the left ven-
tricular mass. Patients with new LE had a decreased left ventricular function (ejection fraction: pre, 55.5  14.1% vs. post,
45.3  14.9%; p ¼ 0.001). In patients without new LE, no differences were observed (ejection fraction: pre, 53.9  17.3%
vs. post, 54.6  16.3%; p ¼ NS) after TAVR.
CONCLUSIONS New ischemic-type myocardial LE after TAVR can be observed in a notable proportion of patients and is
assumed to be of embolic origin. Patients with new LE feature a signiﬁcant decrease in left ventricular function at
discharge. (J Am Coll Cardiol 2014;64:349–57) © 2014 by the American College of Cardiology FoundationT ranscatheter aortic valve replacement (TAVR)has evolved into standard procedure forpatients with aortic stenosis who are at high
risk for conventional surgery (1). The interventional
approach has been shown to be more effective than
standard medical treatment in high-risk patients, but
it is nonetheless associated with relatively high mor-
tality and morbidity (2). Periprocedural myocardial
injury has been identiﬁed as a predictor of unfavorable
outcome after TAVR (3), and various hypotheses exist
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TABLE 1 Baseline C
Characteristics
Demographics
Age, yrs
Female
Cardiac measures
Logistic EuroSCORE
STS PROM score, %
EF, %
Mean AV gradient,
AV area, cm2
GFR, ml/min
Comorbidities
Hypertension
CAD
Hyperlipidemia
Atrial ﬁbrillation
MI history
Diabetes
CABG
Stroke history
Values are mean  SD or
tically signiﬁcant.
AV ¼ aortic valve; CA
COPD ¼ chronic obstru
ﬁltration rate; MI ¼myoc
Mortality; TA ¼ transapic
ABBR EV I A T I ON S
AND ACRONYMS
CK-MB = creatine kinase-
myocardial band
CMR = cardiac magnetic
resonance
EF = ejection fraction
hs-cTnT = high-sensitivity
cardiac troponin T
LV = left ventricular
MI = myocardial infarction
PCI = percutaneous coronary
intervention
TA = transapical
TAVR = transcatheter aortic
valve replacement
TF = transfemoral
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350myocardial infarction (MI)—may be consid-
ered the most appropriate method (6). In the
setting of percutaneous coronary interven-
tion (PCI), a close association has been
described between infarct size determined
by CMR, left ventricular ejection fraction
(LVEF), and biomarker release (7,8); however,
such data on TAVR are currently lacking.
The objectives of our study were to
examine the prevalence and degree of new
areas of late enhancement (LE) as a measure
of myocardial damage in patients undergoing
TAVR and to correlate it with the periproce-
dural rise of myocardial biomarkers.SEE PAGE 358METHODS
PATIENT SELECTION AND PROCEDURAL DATA.
From January 2011 to September 2013, patients with severe
aortic stenosis scheduled for TAVR were enrolled in the
study. Exclusion criteria were as follows: contraindication
for CMR, concomitant PCI, the presence of intracardiac
thrombi, conversion to open heart surgery, major compli-
cations associated with myocardial injury, and the need for
cardiopulmonaryresuscitationorextracorporealcirculation.haracteristics
All Patients
(n ¼ 61)
TA
(n ¼ 26)
TF
(n ¼ 35)
81.9  5.3 81.9  5.9 81.9  4.8
32 (52.5) 15 (57.7) 14 (40.0)
, % 24.0  9.6 24.8  11.2 23.4  8.4
6.3  4.5 6.6  4.8 6.2  4.3
53.5  13.8 53.6  13.3 53.5  14.4
mm Hg 43.4  17.3 44.7  15.6 42.4  18.8
0.7  0.2 0.7  0.3 0.6  0.2
68.6  24.6 69.7  25.2 67.8  24.5
58 (95.1) 26 (100) 32 (91.4)
40 (68.9) 18 (69.2) 22 (62.9)
35 (57.4) 18 (69.2) 17 (48.6)
22 (36.1) 11 (42.3) 11 (31.4)
16 (26.3) 9 (37.6) 7 (20.0)
17 (27.9) 9 (34.6) 8 (22.9)
10 (16.4) 6 (23.1) 4 (11.4)
7 (11.5) 4 (15.4) 3 (8.6)
n (%). None of the differences between the 2 subgroups were statis-
BG ¼ coronary artery bypass graft; CAD ¼ coronary artery disease;
ctive pulmonary disease; EF ¼ ejection fraction; GFR ¼ glomerular
ardial infarction; STS PROM ¼ Society of Thoracic Surgeons Prediction of
al; TF ¼ transfemoral.The ethics committee of theUniversity ofGiessen, Germany
approved the study protocol. Written informed consent
was obtained from all patients. Baseline examinations
including the protocol for multislice computed tomography
are described in the Online Appendix.
Implantations were performed as previously reported
(1,9). In brief, for the transapical (TA) route, balloon-
expandable prostheses (Sapien XT 23, 26, and 29 mm;
Edwards Lifesciences, Irvine, California) were implanted.
For the transfemoral (TF) route, either balloon-expandable
prostheses (Sapien XT 23, 26, and 29 mm) or self-
expandable prostheses (Corevalve revalving system 26,
29, and 31 mm; Medtronic, Minneapolis, Minnesota) were
used. Before intervention, patients received acetylsalicylic
acid 100 mg/d. During the procedure, heparin was admin-
isteredintravenouslyat adosethatmaintainedanactivated
clotting time of >250 s. Immediately after a successful
procedure, patients began to receive clopidogrel 75mg/day
for 3 months, with an initial loading dose of 600 mg.
CMR IMAGING. Baseline CMRwas performed as part of
the pre-interventional evaluation process on a
1.5-T scanner (Sonata, Siemens Medical Solutions,
Erlangen, Germany). The post-interventional scanwas
conducted during the hospital stay, as soon as patients
were appropriately stable. All CMR studies were
evaluated by 2 experienced cardiologists who were
consensus-blinded to the clinical data using custom-
ized software (CAAS, MRV 3.3, PieMedical Imaging BV,
Maastricht, the Netherlands). Further details are pro-
vided in the Online Appendix.
CARDIAC BIOMARKERS. Venous blood samples for
the determination of high-sensitivity cardiac troponin
T (hs-cTnT) and creatine kinase-myocardial band
(CK-MB)were drawn before and at 24, 48, and 72 h after
TAVR. Serumwas processed immediately and frozen at
–80C until assay. cTnT was measured in serum with
the high-sensitivity electrochemiluminescence im-
munoassay (Elecsys Analyzer 2010 hs-cTnT assay,
Roche Diagnostics, Mannheim, Germany), as des-
cribed previously (10).
STATISTICAL ANALYSIS. Continuous variables are
expressed as mean  SD or as median (interquartile
range [IQR]); categorical data are presented as n (%).
Continuous data were compared by use of the Mann-
Whitney signed rank test for paired data and the
Mann-Whitney U test for unpaired data. For cate-
gorical data, the 2-sided Fisher exact test was
applied. Correlation between discrete variables was
assessed with the Pearson product moment correla-
tion. The receiver operating characteristic curve was
analyzed for discrimination of new MIs with bio-
markers; the threshold for hs-cTnT was calculated
using the Youden index. All statistical data were
TABLE 2 Comparison of Patients With New Versus Those
Without New LE After TAVR
LEþ
(n ¼ 11)
LE–
(n ¼ 50) p Value
Demographics
Age, yrs 82.8  5.6 81.7  5.3 NS
Female 7 (63.6) 25 (50.0) NS
Cardiac measures
Logistic EuroSCORE, % 26.1  9.6 23.5  9.7 NS
STS PROM score, % 6.8  4.5 6.2  4.5 NS
EF, % 52.6  15.3 53.7  13.7 NS
Mean AV gradient,
mm Hg
40.5  23.1 44.0  16.1 NS
AV area, cm2 0.6  0.2 0.7  0.2 NS
GFR, ml/min 47.3  18.5 69.9  17.0 0.01
Comorbidities
Hypertension 10 (90.9) 48 (96.0) NS
Diabetes 5 (45.5) 12 (24.0) NS
Hyperlipidemia 4 (36.4) 31 (62.0) NS
Stroke history 2 (18.2) 5 (10.0) NS
MI history 4 (36.4) 12 (24.0) NS
Atrial ﬁbrillation 3 (27.3) 17 (34.0) NS
CAD 5 (45.5) 35 (70.0) NS
Treatment history
Prior PCI 4 (36.4) 20 (40.0) NS
Prior CABG 0 10 (20.0) NS
Statin 9 (81.8) 43 (86.0) NS
Beta-blocker 10 (90.9) 37 (74.0) NS
Arterial characteristics
Dense spontaneous
echo
2 (18.2) 6 (12.0) NS
LAA ﬂow velocity,
cm/s
31.6  12.3 33.8  11.1 NS
Annulus, mm 23.6  1.8 23.3  2.3 NS
MSCT
Calcium score AV 2502.4  1480.3 3023.7  1741.9 NS
Calcium score
coronary arteries
368.7  430.3 796.8  739.5 NS
Distance, annulus–
LCA, mm
12.6  2.2 14.1  3.1 0.09
Distance,
annulus–RCA, mm
14.6  2.5 15.1  3.0 NS
CMR
Scan, days
Baseline 3 (IQR 1-7) 2 (IQR 1-5) NS
After TAVR 7 (IQR 4-7) 6 (IQR 6-7.3) NS
EF, % 55.5  14.1 53.9  17.3 NS
Baseline
After TAVR 45.3  14.9 54.6  16.3 0.08
LV mass, g 142.2  30.3 147.8  46.2 NS
Scar mass, g
Baseline 3.3 (1.7–7.7) 7.0 (0–19.1) NS
% of LV mass 2.9 (1.6–4.5) 4.7 (0–10.4) NS
After TAVR 3.7 (1.2–6.0) 0 <0.001
% of LV mass 1.8 (1.3–4.1) 0 <0.001
EDD, mm 50.6  5.7 48.8  7.9 NS
ESD, mm 32.9  8.7 31.0  10.7 NS
EDV, ml 127.9  37.9 136.5  51.6 NS
ESV, ml 60.1  36.6 68.3  46.7 NS
Continued in the next column
TABLE 2 Continued
LEþ
(n ¼ 11)
LE–
(n ¼ 50) p Value
Biomarkers
hs-cTnT, ng/l
Baseline 25.6 (20.4–59.1) 23.7 (9.5–50.9) NS
Maximal 447 (212–562) 254 (128–504) NS
CK-MB, U/l
Baseline 10.0 (9.0–13.0) 11.0 (9.0–16.0) NS
Maximal 18.0 (14.0–34.0) 21.0 (12.0–34.3) NS
Procedural data
Femoral access 7 (63.6) 28 (56.0) NS
Apical access 4 (36.4) 22 (44.0) NS
Corevalve 4 (36.4) 13 (26.0) NS
Sapien XT 7 (63.6) 37 (74.0) NS
Prosthesis/annulus
ratio
1.12  0.13 1.14  0.09 NS
Balloon/annulus
ratio
0.94  0.14 0.95  0.07 NS
Need for post-dilation 4 (36.4) 9 (18.0) NS
Procedure
duration, min
53.0 (42.0–65.0) 45.0 (36.8–63.3) NS
Fluoroscopy
time, min
10.9 (5.7–20.8) 9.4 (5.4–12.9) NS
Contrast agent, ml 96.8  37.5 84.3  34.6 NS
Values are mean  SD, n (%), or median (interquartile range).
CK-MB ¼ creatine kinase-myocardial band; EDD ¼ end-diastolic diameter;
EDV ¼ end-diastolic volume; ESD ¼ end-systolic diameter; ESV ¼ end-systolic
volume; hs-cTnT ¼ high-sensitivity cardiac troponin T; LAA ¼ left atrial
appendage; LCA ¼ left coronary artery; LE ¼ late enhancement; MCST ¼multislice
computed tomography; NS ¼ not signiﬁcant; PCI ¼ percutaneous coronary inter-
vention; RCA ¼ right coronary artery; TAVR ¼ transcatheter aortic valve
replacement; other abbreviations as in Table 1.
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351analyzed with SPSS version 18.0 (IBM SPSS Statistics,
IBM Corporation, Armonk, New York).
RESULTS
PATIENTS AND PROCEDURAL RESULTS. Eighty-
seven patients who met all of the inclusion criteria
were enrolled, and a baseline CMR was acquired.
In 26 cases, post-procedural CMR was not available
for several reasons: 12 patients required pacemaker
implantation, 6 were in unstable condition, death
occurred in 5 cases (emergency conversion in 3 pa-
tients, 1 case of major stroke, and 1 case of annular
rupture), and 3 patients refused the post-procedural
examination. Therefore, the study protocol was com-
pleted in 61 patients (TF: Sapien XT, n ¼ 18; Core-
valve, n ¼ 17; TA: Sapien XT, n ¼ 26). Baseline
characteristics were similar between the groups with
TA and TF access (Table 1). None of the patients
reported symptoms indicative of MI.
COMPARISON OF PATIENTS WITH NEW LE VERSUS
PATIENTS WITHOUT NEW LE. Except for reduced
renal function in the group with new LE (LEþ), there
were no further signiﬁcant differences in baseline
FIGURE 1 New My
Late enhancement (L
replacement (TAVR).
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352and procedural parameters between the LEþ group
and the group without new LE (LE–), including ﬁnd-
ings on electrocardiography (Table 2, Online Fig. 1).
CMR imaging . The time intervals of baseline CMR to
procedure and from procedure to post-interventional
scans were similar between the LEþ and LE– groups
(Table 2). Image quality overall was appropriate, and
the implanted prostheses did not produce artefacts
that would have interfered with any of the analyses
performed.
The results of the CMR volumetric analyses are
summarized in Table 2. Baseline CMR revealed pre-
existing myocardial ischemic scars in 42 patients
(68.8%), with an average mass of 10.9 g (IQR: 5.1 to
21.9 g) or 7.4% (IQR: 3.9 to 11.7 g) of total LV mass.
Among these patients, 9 of 42 (21.4%) had no relevant
coronary artery disease, and 28 of 42 (66.7%) had no
history of MI. There was no relevant difference in
baseline infarct size between the LEþ and LE– groups
(Table 2).
New hyperenhancement after TAVR was observed
in 11 patients (18%) featuring a primarily sub-
endocardial or intramural localization (Fig. 1, Online
Table 1). The mean mass of new LE was 3.7 g (IQR: 1.2
to 6 g), or 1.8% (IQR: 1.3 to 4.1 g) of total LV mass. The
transmural extents ranged from 25% to <50% in 2 pa-
tients, 50% to <75% in 4 patients, and 75% to 100% in
1 patient. Four patients (36.4%) had intramural lesions
with a viable endocardial rim. The affected coronary
territory involved the left anterior descending artery
in 4 patients, the left circumﬂex artery in 3 patients,
and the right coronary artery in 3 patients. One patient
demonstrated 1 lesion each in the left anterior
descending artery and the left circumﬂex artery.ocardial LE After TAVR
E) images before (A) and after (B) transcatheter aortic valve
The asterisk indicates new myocardial hyperenhancement.There were no signiﬁcant differences with respect
to infarct size, change in EF, and increase in
biomarker levels between the group with a viable
endocardial rim and that without (Online Table 2).
Prior PCI/MI with known coronary artery disease
was present in 5 cases. Four patients had coronary
stenosis of >50% before TAVR, without the need for
revascularization. In only 1 patient with residual
stenosis (>50%) of the right coronary artery, new
myocardial scarring was present in the same coronary
territory, whereas in all of the other patients, there
was no correlation between pre-existing stenosis and
localization of new infarctions.
Whereas LVEF remained similar in the LE– group
(pre, 53.9  17.3% vs. post, 54.6  16.3%; p ¼ NS), LEþ
patients revealed a signiﬁcant post-procedural de-
crease in LVEF (pre, 55.5  14.1% vs. post, 45.3 
14.9%; p ¼ 0.001) (Fig. 2). There was no signiﬁcant
correlation between the mass of new LE and the
decrease in LVEF (R ¼ 0.28; p ¼ NS).
Card iac b iomarkers . The baseline hs-cTnT concen-
tration was 24.9 ng/l (IQR: 11.2 to 51.9) and was above
the 99th percentile (14 ng/l) in 46 cases (75.4%). After
the TAVR procedure, there was an increase in hs-
cTnT levels above the 99th percentile in all patients.
The maximum concentration of hs-cTnT within 72 h
after the procedure was 307.3 ng/l (IQR: 141.2 to
533.8 ng/l), and a 15-fold rise was observed in 61
patients (55.7%) (TF, 10 of 35 [28.5%] vs. TA, 24 of
26 [92.3%]; p < 0.001). The CK-MB concentration
at baseline was 11 U/l (IQR: 9 to 15 U/l) and increased
to a maximum value of 21 U/l (IQR: 13.5 to 34 U/l)
after the procedure, with a 5-fold rise in 26.2% of
the population.
Neither baseline values nor post-operative maxi-
mum concentrations of hs-cTnT and CK-MB were
signiﬁcantly different between the LEþ and LE–
groups (Table 2).
The results of the subgroup analysis according to
the chosen access are depicted in Figures 3 and 4.
Within the TF group, the LEþ subgroup had signiﬁ-
cantly higher maximum concentrations of hs-cTnT
compared with that in the LE– subgroup (242.9 ng/l
[IQR: 167.4 to 457 ng/l] vs. 141.2 ng/l [IQR: 85.9 to
205.9 ng/l]; p ¼ 0.03). In contrast, CK-MB levels were
almost identical between the 2 groups (15 U/l [IQR:
13 to 18 U/l] vs. 14 U/l [IQR: 11 to 20.8 U/l]; p ¼ NS).
The receiver operating characteristic curve of hs-
cTnT maximum values for the detection of new LE
after TAVR revealed an area under the curve of 0.76
(95% conﬁdence interval [CI]: 0.57 to 0.96; p ¼ 0.03).
A threshold of 209 ng/l yielded a sensitivity of 71.4%
and a speciﬁcity of 78.8% (Fig. 5). The area under the
curve for a relative increase in the concentration of
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FIGURE 2 Comparison of EF Between the LEþ and LE– Groups
After TAVR, the mean ejection fraction (EF) remained unchanged from baseline in the LE–
group (left), whereas in the LEþ group it was signiﬁcantly decreased (right). Abbreviations
as in Figure 1.
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FIGURE 3 Post-Procedural hs-cTnT Maximal Values
Maximum values of high-sensitivity cardiac troponin T
(hs-cTnTmax) after TAVR are higher in the transapical group.
Within both the femoral and apical subgroups, hs-cTnT concen-
trations were higher in the LEþ patients, but the difference
was signiﬁcant only within the transfemoral group (p ¼ 0.03).
Abbreviations as in Figure 1.
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353hs-cTnT within the TF group was not signiﬁcant
(0.683; p ¼ 0.26).
Within the TA group, the LEþ subgroup also had a
higher maximum increase in hs-cTnT levels after the
procedure, but the difference was not signiﬁcant
(LEþ, 686.4 ng/l [IQR: 475.4 to 871.6 ng/l] vs. LE–,
473.7 ng/l [IQR: 379 to 784.2 ng/l]; p ¼ NS). Likewise,
maximum values for CK-MB were not signiﬁcantly
different (LEþ, 36.5 U/l [IQR: 32.5 to 46.5 U/l] vs. LE–,
31 U/l [IQR: 25 to 42.3 U/l]; p ¼ NS).
DISCUSSION
In the present study, we demonstrated that new
ischemic-type hyperenhancement detected by CMR
occurs in a notable proportion of patients undergoing
TAVR (Central Illustration). The small size, sub-
endocardial or intramural localization, and multifocal
distribution of the lesions are ﬁndings that suggest an
embolic origin. Furthermore, the prevalence of such
lesions, which in most cases were considered not
deﬁnitely related to a relevant coronary stenosis or
coronary artery calcium, argues in favor of an embolic
cause and at the same time makes other potential
causes, such as global or regional hypoperfusion,
rather unlikely. Experimental data derived from
balloon valvuloplasty of calciﬁed porcine aortic
valves provide evidence for embolization of multiple,
small particles in both coronary arteries and thereby
support our hypothesis (11). This suggested mecha-
nism corresponds well to the previously described
ﬁnding that cerebral embolism occurs in up to 84% of
patients after TAVR (12).
CMR is acknowledged to be the most appropriate
method for the detection and quantiﬁcation of infarct
size (6). Its value has been described for the imaging
of periprocedural myocardial necrosis after PCI
(7,8). Ricciardi et al. (8) reported a median mass of
myocardial lesions after PCI of 2 g or 1.5% of left
ventricular mass, which is within a range similar to
that in our observations. The minimally detectable
masses of 0.7 g or 0.8 g in these studies and 0.5 g in
our own results indicate a very high sensitivity of this
method. By contrast, clinical or electrocardiographic
parameters were of limited value for the diagnosis of
MI in our study. Therefore, CMR proves to be a useful
imaging modality for the description of ischemic
lesions and should be considered a complementary
method for future studies on myocardial alterations
after TAVR.
To our knowledge, this is the ﬁrst publication
showing that TAVR is associated with visible, localized
damage of the myocardium. Two recently published
studies describe CMR performed before and 6 monthsafter TAVR, with evidence of new hyperenhancement
in 1 patient each at 6 months, but due to the long
follow-up interval, these lesions could not be attrib-
uted to the procedure (13,14). A direct comparison
p = ns
p = ns
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FIGURE 4 Post-Procedural CK-MB Maximal Values
Maximal values of creatine kinase-myocardial band (CK-MBmax)
after TAVR were higher in the transapical group. Within both the
apical and femoral subgroups, CK-MB concentrations were
numerically but not statistically signiﬁcantly higher in the LEþ
patients. Abbreviations as in Figure 1.
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FIGURE 5 hs-cTnT for Detection of Myocardial Infarction
After TAVR
The receiver operating characteristic (ROC) curve of hs-cTnT
maximal values for the detection of new LE after transfemoral
TAVR revealed an area under the curve of 0.76. A threshold of
209.0 ng/l yielded a sensitivity of 71.4% and a speciﬁcity of
78.8%. MI ¼ myocardial infarction; other abbreviations as in
Figures 1, 3, and 4.
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354with our results is difﬁcult because these studies
focused on various key aspects and had a different
patient population with a lesser age, minor-risk
proﬁle, and smaller patient numbers. Furthermore,
infarcted areas may shrink considerably over time and
might become subsequently unnoticeable.
CARDIAC BIOMARKERS. A post-procedural elevation
of cardiac biomarker levels was observed in all pa-
tients, indicating that myocardial damage commonly
occurs to varying degrees. We further noted a lack
of correlation between the level of cardiac biomar-
kers and the mass of new myocardial hyperenhance-
ment detected by CMR; this is in contrast to the
setting of PCI, in which such an association has been
described to be common (7,8). Myocardial damage
after PCI can mostly be attributed to distal emboli-
zation, whereas in TAVR multiple underlying mech-
anisms may be assumed.
Myocardial biomarker concentrations did not
discriminate between patients with new LE and
those without. Only the subgroup analysis revealed
signiﬁcantly higher concentrations of hs-cTnT in the
TF group with new LE than in those without. In the
TA group, patients with new hyperenhancement also
had numerically higher levels of hs-cTnT, but the
difference was not signiﬁcant; this ﬁnding can beascribed to the overall higher values caused by the
apical trauma. In addition, despite signiﬁcantly
higher biomarker concentrations in the LEþ patients,
there was no linear correlation between hs-cTnT
concentration and the mass of new myocardial le-
sions. However, due to the small patient numbers,
this subgroup analysis is of limited statistical validity.
The inverse relationship between reduced renal
function and higher troponin levels iswell-known, and
we cannot fully exclude that increased troponin con-
centrations in the LEþ group may be ascribed to some
extent to the differences in renal function. Nonethe-
less, despite lower GFR in LEþ patients, biomarker
levels at baseline were similar between these 2 groups,
so at the least, the initial conditions were comparable.
We assume that the TAVR procedure is associated
with multiple confounding factors that contribute to
myocardial damage. Elevated cardiac biomarkers
certainly indicate myocardial injury, but an explicit
attribution to a deﬁnite cause is difﬁcult.
IMPACT ON LV FUNCTION. In our study population,
LEþ patients had a signiﬁcant decrease in LVEF after
TAVR, whereas LVEF in the LE– group remained
unchanged. The relatively small mean lesion size of
CENTRAL ILLUSTRATION Mechanisms of Periprocedural Myocardial Injury in
Cardiac Interventional Procedures
This table summarizes various mechanisms of myocardial damage and their clinical im-
plications in selected cardiac interventions. The described patterns may be subdivided into
classic myocardial infarction (types 2 and 4) and miscellaneous forms including procedure-
related injury (e.g., apical access, trans-septal puncture) or mechanical irritation (e.g.,
balloon valvuloplasty, catheter manipulation). Notably, coronary embolism is a compli-
cation that is common to many interventional procedures. PCI ¼ percutaneous coronary
intervention; TAVR ¼ transcatheter aortic valve replacement.
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3552.6% of LV mass certainly would not explain this
considerable decrease in LVEF. Accordingly, a CMR
study in patients with troponin elevation after
PCI and evidence of new hyperenhancement with
a mean of even 5% of LV mass demonstrated no
change in LVEF (7). Several experimental studies
may help to understand this observation. It has been
demonstrated that brief episodes of myocardial
ischemia may cause prolonged impairment of con-
tractile function on reperfusion (15), which can last
up to 1 week and even longer in cases of repetitive
myocardial ischemia (16). Experimental animal
models with coronary microembolization have indi-
cated that an inﬂammatory reaction may play a
crucial role in the development of contractile
dysfunction, independent of infarct size (17). With
respect to TAVR, we assume that the evidence of
new myocardial lesions probably indicates a rele-
vant exposure to microemboli but does not allow
for a hypothesis on the exact amount and size of
the embolic load. Studies with coronary protection
devices have revealed that nearly all coronary in-
terventions are associated with distal embolization
of small particles, but an elevation of myocardial bio-
markers is found in only 5% to 40% (18). This ﬁnding
leads to the hypothesis that embolized particles do not
always cause measurable necrosis of myocytes and
also might partially explain why new myocardial
hyperenhancement was not evident in all patients af-
ter TAVR. Rather, those lesions might represent only
the visible proportion of the true coronary embolic
load, essentially the “tip of the iceberg.”
The transapical access inevitably causes a localized
defect of the apex. An echocardiographic study has
demonstrated that post-operative apical dysfunction
developed in 28% of patients and completely resolved
in half of those patients (19). However, global LV
function has been shown to be unaffected by these
localized and often transient wall-motion abnormal-
ities and seems to rather improve over time (20).
Therefore, we presume that the impact of the apical
approach on global LV function can be neglected.
CLINICAL IMPLICATIONS. According to the revised
Valve Academic Research Consortium (VARC II)
criteria, 36 patients (59%) had a periprocedural MI,
which is in clear contrast to our CMR results showing
proof of MI in only 18% (21). The 25 subjects (41%)
without morphological evidence of a localized myo-
cardial lesion as revealed by CMR had a TA approach
in most cases (88%), which explains the relevant in-
crease in hs-cTnT. Therefore, we conclude that the
biomarker-based VARC II criteria fail to sufﬁciently
discriminate patients with MI—especially in cases ofthe TA approach. Given the lack of an apical trauma,
the diagnostic use of cardiac biomarkers for the
detection of MI might at best be considered in TF pa-
tients, which in our study yielded a sensitivity of
71.4% and a speciﬁcity of 78.8% for an hs-cTnT level of
209 ng/l. Interestingly, these values approximately
correspond to the threshold of a 15-fold rise of hs-
cTnT as deﬁned by VARC II. In this regard, it may be
of reasonable interest whether this subset of patients
might beneﬁt from dual-antiplatelet therapy for 12
months, as recommended in current guidelines (22).
Thus far, there is no evidence supporting the pre-
sent practice of administering acetylsalicylic acid
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Ischemic myocardial hyperenhancement detected by
CMR imaging develops in some patients after TAVR
and may be a more speciﬁc diagnostic marker of
myocardial injury after TAVR than clinical, electro-
cardiographic, or biomarker criteria, which are often
inconclusive.
TRANSLATIONAL OUTLOOK 1: Additional obser-
vational and prospective studies are warranted to
correlate biomarker and serial CMR studies and
establish the prognostic implications of myocardial
injury detected by the various methods in patients
undergoing TAVR.
TRANSLATIONAL OUTLOOK 2: Myocardial injury
detected by CMR may be caused by embolism related
to catheter manipulations in patients undergoing
TAVR, and more research is needed to conﬁrm this
mechanism and to develop improved valve prosthe-
ses, delivery systems, and myocardial protection
strategies.
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356100 mg/d and clopidogrel 75 mg/d for 3 to 6 months
after TAVR. The development of coronary protective
devices or valve prostheses and delivery systems with
protective features should be the subject of future
investigations.
STUDY LIMITATIONS. Our hypothesis cannot be
deﬁnitively proven with the methods applied in our
study. Our data did not point out clinical or procedural
predictors expected to be associated with new-onset
LE, including the need for post-dilation, procedural
duration, extent of aortic valve calciﬁcation, and the
chosen access (Table 2). Only renal function was
signiﬁcantly decreased in the LEþ group, which might
indicate an unhealthier population more prone to
myocardial damage. Further limitations of our study
were the rather small sample size from a single center
and the inhomogeneity of the patient cohort due to
different TAVR approaches and various valve types
implanted; thus, the presented rate of patients with
new myocardial injury should be interpreted with
caution. At the least, an access-related bias seems to
be of minor relevance, given the similar baseline
characteristics between the TA and TF groups.
CONCLUSIONS
New ischemic-type myocardial LE after TAVR was
observed in a notable proportion of patients and is
assumed to be of embolic origin. These patients
featured a signiﬁcant decrease in LV function at
discharge. Although elevation of cardiac biomarkers
is common after TAVR, it cannot be clearly related to
the myocardial alterations measured with CMR due tothe multifactorial causes of periprocedural myocar-
dial injury.
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